Biogen Seeks to Stand Out in Lupus With New Anti-CD40L Data
Phase III data for dapirolizumab pegol presented at the 2025 conference of the American College of Rheumatology showed quality-of-life benefits in systemic lupus erythematosus that could see Biogen go head-to-head with GSK and AstraZeneca in a blockbuster space.
Biogen Seeks to Stand Out in Lupus With New Anti-CD40L Data Read More »
